Lung cancer PDX
Angiogenesis is closely associated with tumorigenesis, progression, metastasis, and prognosis of lung cancer. This also include neovascularization with unrestricted proliferation of tumor cells. In addition, anti-angiogenic monotherapy has limited clinical efficacy, and drug resistance is evident. As a result, the "A+A" strategy (the combination of two or more anti-angiogenic medications targeting various angiogenic signaling pathways) is thought to achieve more potent anti-tumor effects. Avastin and Erlotinib, for example, were recently approved for the treatment of NSCLC with EGFR-activating mutations, and the results were verified by a phase III clinical trial (NEJ026).
At present, GemPharmatech' extensive collection possesses 6 cases of PDX tumor samples of Lung Cancer.
PDX ID | Histological type | Grade | Stage | WES | RNA-seq |
LC00136 | Lung Squamous Cell Carcinoma | Low to medium differentiation | N/A | Y | Y |
LC00140 | Lung Squamous Cell Carcinoma | Moderate-severe differentiation | N/A | Y | Y |
LC00143 | Lung Adenocarcinoma | N/A | ⅡA (T2b N0 cM0) | Y | Y |
LC00167 | Lung Squamous Cell Carcinoma | N/A | N/A | N/A | Y |
LC00202 | Small Cell Lung Cancer | Poorly differentiated | N/A | Y | Y |
LC00256 | Lung Squamous Cell Carcinoma | Moderately differentiated | ⅠA3(pT1cN0cM0) | Y | Y |